Friday, 17 Aug 2018

You are here

Salt Drives Gut-Brain Connection via IL-17

A study from Nature Neuroscience shows that a high salt diet may mediate neurovascular disease by altering microbiome and the expansion of TH17 cells in the small intestine, thereby increasing plasma interleukin-17 (IL-17) and its subsequent effects on endothelium in the brain.

While studies have suggested that salt may be linked to increased risk of cerebrovascular diseases and dementia, the mechanisms have not been elucidated.

Researchers showed that mice fed a high salt diet had suppressed cerebral blood flow and endothelial function, leading to cognitive impairment and a decrease in blood flow to the cortex and hippocampus.

This was shown to be dependent on expansion of TH17 cells in the small intestine, resulting in a marked increase in plasma interleukin-17 (IL-17).  Circulating IL-17 mediates endothelial dysfunction and cognitive impairment by the Rho kinase–dependent inhibitory phosphorylation of endothelial nitric oxide synthase and reduced nitric oxide production in cerebral endothelial cells.

When the high-salt diet was discontinued, the cognitive performance of mice was restored.

The findings reveal a new gut–brain axis linking dietary habits to cognitive impairment through a gut-initiated adaptive immune response compromising brain function via circulating IL-17.

Such findings may extend beyond neurologic disorders and may impact diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease, as each of these are markedly impacted by Th17 cells and IL-17. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Back Pain in Psoriatic Arthritis

A single center study of psoriatic arthritis patients has shown that rheumatologist-judged inflammatory back pain (IBP) and criteria defining IBP may not perform well when ascertaining axial involvement in PsA patients. 

Minimal Disease Activity: The Goal in PsA

The majority of patients with psoriatic arthritis (PsA) who achieved a state of minimal disease activity (MDA) after 6 months of treatment with adalimumab (Humira) maintained that response through 24 months, a large observational study found.

Liver Disease Increased in Psoriasis

An observational case-control study has shown that psoriasis is associated with an increased prevalence of nonalcoholic fatty liver disease (NAFLD).

A single center, outpatient dermatology clinic studied 151 patients with psoriasis and 51 control subjects with ultrasonography to diagnose NAFLD.

Best of 2017: Cause of Death in Ankylosing Spondylitis

A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology.

They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009).

The mortality rate of AS remained stable over time.

Ixekizumab Effective in Ankylosing Spondylitis

Eli Lilly announced today the results of the COAST-W trial showing that ixekizumab (Taltz) was effective in a Phase 3 study Ankylosing Spondylitis (AS) patients who had an inadequate response or intolerance to tumor necrosis factor (TNFi) inhibitor therapy.